Portugal
FairJourney Bio specializes in cutting-edge antibody discovery and development. Established in 2012, the company offers comprehensive end-to-end solutions designed to accelerate research. With over a decade in the field, their innovative technologies and highly skilled team have successfully advanced 19 antibodies to clinical stages, showcasing their proficiency and reliability.
Their adaptable partnership model is a key strength, allowing them to support projects of varying scales. This flexibility positions FairJourney Bio as an attractive partner for entities ranging from early-stage research ventures to more developed projects, offering customized, high-quality antibodies that align with specific project needs.
Despite no recent investment details available, their track record underscores their potential for growth and contributions to global healthcare. Investing in FairJourney Bio could present a unique opportunity for those looking to support revolutionary strides in therapeutic discovery.
